Table 1 Characteristics of the included studies and participants studies
First author (year) | Country | Total participants (N) | Total participants in intervention groups (n) | Prevalence AL (%) | Male-to-female ratio evaluated (T, I, C) | Age, years (y) Mean ± SD | Neoadjuvant therapy | Follow-up, months (mo, wk, or y) Mean ± SD |
|---|---|---|---|---|---|---|---|---|
Bhat 2006 [6] | India | 194 | 97 | 8.8 | T: 3:1.8 | T: 52.5 | Excluded patients with previous neoadjuvant Tx | F/U every 3-mo for 3 y postop every 4- to 6-mo postop |
Dai 2011 [5] | China | 253 | 127 | 3.1 | T: 4:01 | T: 63.5 | Excluded patients with previous neoadjuvant Tx | *22 mo (3–52 mo) |
Daryaei 2008 [19] | Iran | 40 | 18 | 15 | NR | T: 58.4 ± 10.3 | NP | NP |
Gupta 2001 [20] | India | 100 | 48 | 12 | I: 0.8:1 C: 0.7:1 | I: 51.3 ± 13.0 C: 50.8 ± 13.2 | Rad ± Chemo: 22/100 and Chemo alone: 56/100 | 3 mo or more |
Hayashi 2019 [21] | Japan | 71 | 34 | 5.6 | T: 6:8 | T: 63.04 | NP | NP |
Law 1997 [22] | Hong Kong | 122 | 61 | 3.3 | I: 7.7:1 C: 6.6:1 | I: 64 ± 1.2 C: 63 ± 1.0 | NP | 20 (SD 2.2) mo hand-sewn and 19 (2.2) mo stapled group (p = NS) |
Liu 2014 [7] | China | 378 | 188 | 4.2 | T: 3:01 | T: 64 | Excluded patients with previous neoadjuvant Tx | NP |
Liu 2015 [23] | China | 432 | 219 | 5 | I: 3:1 C: 3:1 | I: 62 ± 8 C: 61 ± 9 | Rad + chemo: 64/478 | 17.8 (3.2) mo hand-sewn and 18.3 (3.4) mo stapled |
Luechakiettisak 2008 [24] | Thailand | 104 | 52 | 4.8 | I: 4.8:1 C: 5.6:1 | I: 63.6 C: 62.0 | NP | NP |
Mistry 2012 [25] | India | 253 | 127 | 3.1 | T: 2.1:1 | I: 53.4 C: 56.7 | Rad ± Chemo: 2/150 and Chemo alone: 72/150 | NP |
Nederlof 2011 [26] | Netherlands | 128 | 64 | 31 | I: 2:1 C: 7:1 | I: 60 C: 63 | Rad + Chemo: 27/64 and Chemo alone: 17/64 | 3- or 6-wk outpatient visit. 3 mo first y postop. Every 4 mo second y postop |
Okuyama 2007 [27] | Japan | 32 | 14 | 12 | I: 13:1 C: 16:2 | I: 63.6 C: 64.3 | Excluded patients with previous neoadjuvant Tx | 5 y |
Saluja 2012 [28] | India | 174 | 87 | 17 | I: 2.3:1 C: 1.6:1 | I: 51.4 ± 12 C:50.9 ± 14 | Rad + Chemo: 107/174 | NP |
Zhang 2010 [29] | China | 516 | 272 | 1.4 | I: 1.4:1 C: 1.4:1 | I: 59 ± 1.2 C: 60 ± 1.3 | Excluded patients with previous neoadjuvant Tx | 12 mo |
Zheng 2013 [4] | China | 164 | 82 | 8.5 | I: 1.6:1 C: 1.4:1 | I: 67.5 ± 11.2 C: 65.7 ± 9.4 | None of the patients received chemotherapy or radiotherapy pre-op | 3 y |
Tabira 2004 [30] | Japan | 44 | 22 | 14 | I: 6.3:1 C: 10:1 | I: 64 ± 8 C: 60 ± 8 | NP | NP |
Valverde 1996 [31] | France | 152 | 78 | 16 | I: 9.6:1 C: 10.1:1 | I: 59 ± 9 C: 59 ± 10 | NP | NP |